Glucosidic Astaxanthin Membrane Potential Normalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and other diseases like arthritis, diabetes, lupus, and dementia fail to effectively restore normal membrane electrical potential, reduce intracellular sodium concentrations, increase delivery of magnesium and potassium, eliminate excess reactive oxygen species, and inhibit PD-L1/PD-L2 deactivation of T cells, leading to abnormal cellular functions and cancer cell growth.
Innovation Solution
Administration of a therapeutic amount of glucosidic astaxanthin, prepared by reacting astaxanthin with a monosaccharide at a microwave frequency, which is added to a carrier material and administered orally or dermally, to normalize cell membrane electrical potential, inhibit PD-L1/PD-L2, and increase intracellular delivery of essential ions and nutrients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for cancer and other diseases, then conventional therapy is provided, but normal membrane electrical potential is not restored and intracellular sodium concentrations are not reduced
Solution Approach 1:
The patent uses astaxanthin to change the electrical parameters of cell membranes, specifically restoring membrane potential and altering ion concentrations. This involves changing the electrical charge distribution across cell membranes and modifying the permeability properties of membrane structures, thereby correcting abnormal cellular functions without toxic side effects.
2Reliability
If astaxanthin is administered to normalize cell membrane electrical potential, then membrane potential is restored and PD-L1/PD-L2 is inhibited, but the complexity of the treatment mechanism increases
Solution Approach 1:
Astaxanthin serves as an intermediary substance that mediates between the administered treatment and the cellular targets. It accumulates in cell membranes and acts as a natural PD-L1/PD-L2 inhibitor while simultaneously restoring membrane potential, providing multiple therapeutic effects through a single natural compound rather than requiring complex combination therapies.
3Quantity of substance
If glucosidic astaxanthin is prepared by reacting astaxanthin with monosaccharide using microwave frequency, then absorption and bioavailability are improved, but the manufacturing process complexity increases
Solution Approach 1:
The patent employs microwave heating to induce phase transitions and rapid heating during the glucosidation reaction process. This allows for efficient chemical modification of astaxanthin with monosaccharides, creating glucosidic derivatives with improved solubility and bioavailability. The microwave energy enables rapid and uniform heating that facilitates the chemical reaction while maintaining product quality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method stabilizes sodium and potassium ion gradients, converts anaerobic mitochondrial production to aerobic, reduces inflammation, and leads to apoptosis of cancer cells by normalizing cell membrane capacitance and electrical polarization, without observable side effects.
Implementation Method 1
The high electrode negativity of astaxanthin is a direct result of its hydroxyl and ketone functional groups (carboxylic acid groups) established on both ends of a carbon chain of alternating double bonds. This 'dumbbell' shaped molecule has a central region of electrons that can be donated or adsorbed to reduce a reactive oxidizing molecule, such as PD-1, PD-L1 and PD-L2.
Implementation Method 2
Astaxanthin, as a free radical scavenger/antioxidant, is 400 times more reactive as an antioxidant than betacarotene.
Implementation Method 3
The astaxanthin is reacted with a monosaccharide at a microwave frequency of between 1 and 100 GHz for at least one second and no more than twenty-five seconds.
Data Source
AI summary
A method of treating a subject afflicted with cancer, arthritis, diabetes, lupus, fibromyalgia or dementia includes administering a therapeutic amount of a glucosidic astaxanthin to the subject in need of such treatment. The glucosidic astaxanthin is prepared by reacting astaxanthin with a monosaccharide at a temperature so as to produce the glucosidic astaxanthin. The therapeutic amount is not is greater than 0.1 milligrams per kilogram of body weight per day. The glucosidic astaxanthin can be added to a carrier material, such as an edible material, a pill, or oil.